Sitagliptin accepted as monotherapy in Scotland
By Tom Moberly, 20 July 2010
Sitagliptin has been accepted for restricted use as monotherapy for type-2 diabetes in the NHS in Scotland.
Thee Scottish Medicines Consortium (SMC) has accepted the treatment for patients with type-2 diabetes for whom both metformin and sulphonylureas are inappropriate.
The SMC said that research had shown sitagliptin worked as well as metformin in patients who had received no previous treatment for diabetes.
But, it added, no data are available to compare the effectiveness of sitaglipin with other medicines taken as monotherapy.
- Related Drug Categories
- Insulins
Additional Information
Latest jobs Jobs web feed
- Salaried GP The Practice plc £75-85k FTE +NHS pension, Ely or Leicester
- Regional Clinical Leads The Practice plc Salary £95-105k FTE + NHS pension, Leicester or Sheffield
- Salaried/Lead GPs Malling Health Competitive, role dependant, NHS Pension and defence fees reimbursed, Nationwide
- Newly qualified GP's dr-locums £70 an hour plus, Nationwide
- Full Time Partner (9 sessions) Charnwood Community Medical Group Equal share partner, Loughborough, LEICS
- Locum GP Meddoc Locums £600-£800 A day, London & Essex
Most read
- Health secretary says GPs have 'ethical duty' to save NHS costs
- GPs face 'outcomes targets overload', patient group warns
- LMCs Conference 2012 - Live Blog
- QOF errors trigger £1,000 top ups and clawbacks
- Women to be screened later for cervical cancer in Scotland and Wales
- LMCs conference 2012 - Full coverage
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
